|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Stivarga
|
|
gptkbp:activities
|
tyrosine kinase inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Stivarga
|
|
gptkbp:class
|
arylurea
|
|
gptkbp:clinical_trial
|
combination therapy
Phase III
monotherapy
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Bayer_AG
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:effective_date
|
gptkb:2012
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:has_ability
|
80 mg
40 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
regorafenib
|
|
gptkbp:indication
|
gptkb:gastrointestinal_stromal_tumors
gptkb:healthcare_organization
gptkb:hepatocellular_carcinoma
|
|
gptkbp:ingredients
|
C21 H21 Cl F2 N4 O3 S
|
|
gptkbp:interacts_with
|
gptkb:warfarin
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
2028
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
approximately 30 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research_areas
|
drug development
oncology
pharmacology
clinical pharmacology
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
hypertension
vomiting
diarrhea
rash
stomatitis
liver function abnormalities
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:targets
|
angiogenesis
|